` LDX (Lumos Diagnostics Holdings Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

LDX
vs
S&P/ASX 300

Over the past 12 months, LDX has underperformed S&P/ASX 300, delivering a return of -55% compared to the S&P/ASX 300's 11% growth.

Stocks Performance
LDX vs S&P/ASX 300

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LDX vs S&P/ASX 300

Loading
LDX
S&P/ASX 300
Difference

Performance By Year
LDX vs S&P/ASX 300

Loading
LDX
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Lumos Diagnostics Holdings Ltd vs Peers

S&P/ASX 300
LDX
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Lumos Diagnostics Holdings Ltd
Glance View

Market Cap
27.7m AUD
Industry
Health Care

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX Intrinsic Value
0.168 AUD
Undervaluation 78%
Intrinsic Value
Price
L
Back to Top